OptimizeRx Q4 results ‘at odds with muted’ outlook, says Roth MKM

Roth MKM reiterates a Buy rating on OptimizeRx (OPRX) with a $16 price target following the Q4 report. The company reported “strong” results which are “at odds” with its “muted” 2025 guidance, the analyst tells investors in a research note. Roth says with its newest “DAAP” offering doubling revenue generating deals year-over-year, and with net dollar retention of 121%, it views the 2025 guidance of at least $100M in revenue as “overly conservative.” It believes OptimizeRx’s “strong pattern of beating estimates” should result in 2025.